Literature DB >> 12006925

Evaluation of toxicity and quality of life using a diary card during postoperative radiotherapy for rectal cancer.

Orazio Caffo1, Maurizio Amichetti, Mario Romano, Sergio Maluta, Luigi Tomio, Enzo Galligioni.   

Abstract

PURPOSE: Adjuvant pelvic radiotherapy after radical surgery for rectal cancer may produce several side-effects (mainly gastrointestinal) capable of affecting patient lifestyle. This prospective study evaluated by means of a diary card the toxicity and daily changes in the quality of life of patients with rectal cancer treated with postoperative pelvic radiotherapy.
METHODS: We used a diary card listing ten items about lifestyle changes and side-effects compiled by patients themselves. The patients were stratified by age (< or = 65 vs. > 65 years), the presence or not of a stoma, and the administration or not of concurrent chemotherapy.
RESULTS: Twenty-seven patients were evaluable. The mean number of bowel movements increased across time, without statistically significant differences. Nausea and appetite did not significantly change during the treatment period. There was a statistically significant, progressive increase in the perception of pain (P < 0.03). Although not significantly, the anxiety scores were lower during radiotherapy than at baseline. Daily activities and compliance with therapy did not significantly change during the treatment. There was a significant worsening in overall well-being (P < 0.04) and quality of life evaluation (P < 0.03). The patients who received chemoradiotherapy experienced a worsened lifestyle and greater side-effects. Older patients experienced less pain but had statistically significant higher levels of anxiety. Patients with a stoma reported a better quality of life score than those without.
CONCLUSIONS: The use of a diary card may be an adequate means of detecting the extent of treatment-related changes in the lifestyle of patients with rectal cancer treated by postoperative radiotherapy.

Entities:  

Mesh:

Year:  2002        PMID: 12006925     DOI: 10.1007/s10350-004-6220-2

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  5 in total

1.  Quality-of-life and surgical treatments for rectal cancer--a longitudinal analysis using the California Cancer Registry.

Authors:  Julie Smith-Gagen; Rosemary D Cress; Christiana M Drake; Patrick S Romano; Kathleen J Yost; John Z Ayanian
Journal:  Psychooncology       Date:  2010-08       Impact factor: 3.894

2.  Functional deficits and symptoms of long-term survivors of colorectal cancer treated by multimodality therapy differ by age at diagnosis.

Authors:  Christina E Bailey; Hop S Tran Cao; Chung-Yuan Hu; George J Chang; Barry W Feig; Miguel A Rodriguez-Bigas; Sa T Nguyen; John M Skibber; Y Nancy You
Journal:  J Gastrointest Surg       Date:  2014-09-12       Impact factor: 3.452

Review 3.  Synthesis and summary of patient-reported outcome measures to inform the development of a core outcome set in colorectal cancer surgery.

Authors:  A G K McNair; R N Whistance; R O Forsythe; J Rees; J E Jones; A M Pullyblank; K N L Avery; S T Brookes; M G Thomas; P A Sylvester; A Russell; A Oliver; D Morton; R Kennedy; D G Jayne; R Huxtable; R Hackett; S J Dutton; M G Coleman; M Card; J Brown; J M Blazeby
Journal:  Colorectal Dis       Date:  2015-11       Impact factor: 3.788

Review 4.  Adjuvant radiotherapy for the treatment of stage IV rectal cancer after curative resection: A propensity score-matched analysis and meta-analysis.

Authors:  Min Jung Kim; Sang Jin Kim; Sung-Chan Park; Dae Yong Kim; Ji Won Park; Seung-Bum Ryoo; Seung-Yong Jeong; Kyu Joo Park; Heung Kwon Oh; Duck-Woo Kim; Sung-Bum Kang; Jung Nam Joo; Jae Hwan Oh
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 5.  Understanding the psychosocial impact of colorectal cancer on young-onset patients: A scoping review.

Authors:  Athena Ming-Gui Khoo; Jerrald Lau; Xin-Sheng Loh; Celeste Wen-Ting Ng; Konstadina Griva; Ker-Kan Tan
Journal:  Cancer Med       Date:  2022-02-11       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.